WallStSmart

Eli Lilly and Company (LLY)vsWW International, Inc. Common Stock (WW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 9072% more annual revenue ($65.18B vs $710.64M). WW leads profitability with a 148.6% profit margin vs 31.7%. LLY appears more attractively valued with a PEG of 1.29. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06

WW

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 5.5Value: 5.7Quality: 6.5
Piotroski: 4/9Altman Z: 12.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$760.43B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

WW5 strengths · Avg: 10.0/10
P/E RatioValuation
1.3x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Profit MarginProfitability
148.6%10/10

Keeps 149 of every $100 in revenue as profit

EPS GrowthGrowth
5268.0%10/10

Earnings expanding 5268.0% YoY

Altman Z-ScoreHealth
12.9910/10

Safe zone — low bankruptcy risk

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.0x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
28.7x2/10

Trading at 28.7x book value

WW4 concerns · Avg: 2.8/10
Market CapQuality
$97.97M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Debt/EquityHealth
1.453/10

Elevated debt levels

PEG RatioValuation
4.922/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bull Case : WW

The strongest argument for WW centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 148.6% and operating margin at -5.4%.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Bear Case : WW

The primary concerns for WW are Market Cap, Return on Equity, Debt/Equity.

Key Dynamics to Monitor

LLY profiles as a growth stock while WW is a declining play — different risk/reward profiles.

WW carries more volatility with a beta of 1.06 — expect wider price swings.

LLY is growing revenue faster at 42.6% — sustainability is the question.

LLY generates stronger free cash flow (678M), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 56/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

WW International, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?